Drugs used in Diabetes
Overview
This report looks at prescribing trends in primary care for Drugs used in Diabetes at SICBl and ICB level with particular focus on insulins, anti-diabetic drugs and diagnostic & monitoring devices. Prescribing data is weighted with QoF registers, and also uses HES data to measure prescribing to outcomes.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
January 2020 to December 2022
Growth Contrast Tool
Overview
The growth contrast tool is intended to help ICBs identify important local effects on prescribing costs. The figures are derived by comparing growth in prescribing costs and items in selected SICBLs with what might have happened if national growth patterns had applied. Comparing actual growth with counterfactuals based on national growth patterns should remove the effect of system-wide changes (e.g. price increases, patent expiries, discontinuations, shortages, implementation of national guidance, etc.) & bring local effects into focus.
Data Period
April 2022 to December 2022
Frequency
Quarterly
Top 50 BNF sections and drugs
Overview
This report looks at the top 50 BNF sections and drugs in terms of spend at SICBL level for the financial year to date with a focus on cost growth and item growth.
Frequency
Quarterly
Data period
April 2022 to December 2022
Formulary assessment – Morphine sulfate (Actimorph) orodispersible tablets
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Drugs for Dementia
Overview
This report looks at prescribing trends in primary care for Drugs for Dementia at SICBl and ICB level with particular focus on low strength antipsychotics. Prescribing data is weighted with QoF registers.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
January 2020 to December 2022
Cardiovascular System
Overview
This report looks at prescribing trends in primary care for the Cardiovascular System at SICBl and ICB level with particular focus on anticoagulants, antiplatelets and lipid-regulating. Prescribing data is weighted with QoF registers, and also uses HES data to measure prescribing to outcomes. The report also calculates the potential opportunity cost for cardiovascular drugs based on the NHS England Right Care indicators.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
January 2020 to December 2022
Respiratory System
Overview
This report looks at prescribing trends in primary care for the Respiratory System at SICBl and ICB level with particular focus on bronchodilators and corticosteroids. Prescribing data is weighted with QoF registers, and also uses HES data to measure prescribing to outcomes. The report also calculates the potential opportunity cost for respiratory drugs based on the NHS England Right Care indicators.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
January 2020 to December 2022
Antibacterial drugs
Overview
This report looks at prescribing trends in primary care for Antibacterial drugs at SICBl and ICB level with particular focus on prescribing volume of antibacterial agents such as cephalosporins, quinolones, macrolides and tetracyclines. Prescribing data is weighted with STAR-PU prescribing measures, and incorporates C. difficile rates and non-medical prescribing.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
January 2020 to December 2022
Prescribing Update Newsletter – December 2022
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
This month’s edition focuses on polypharmacy, influenza in the community – prescribing antivirals, group A streptococcus in children – advice for clinicians, and the MHRA review on the safe use of valproate. We also include recent publications from the RDTC and another in the series of “Meet the Team” where you can get to know the people behind the work we do. There is also information on some key medicines availability issues and serious shortage protocols.
Monthly Horizon Scanning Report – December 2022
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.